Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection
暂无分享,去创建一个
Esteban A. Hernandez-Vargas | Alessandro Boianelli | Dunja Bruder | D. Bruder | E. Hernández-Vargas | Alessandro Boianelli | Niharika Sharma-Chawla | Niharika Sharma-Chawla
[1] Melissa Carter,et al. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. , 2009, The Journal of infectious diseases.
[2] Jo Leonardi-Bee,et al. Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients , 2012, The Journal of infectious diseases.
[3] C. Beauchemin,et al. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms , 2017, PloS one.
[4] E. D. Kilbourne. Influenza Pandemics of the 20 th Century , 2005 .
[5] Larisa V. Gubareva,et al. Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.
[6] Larisa V. Gubareva,et al. Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.
[7] Andreas Handel,et al. A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead , 2011, BMC public health.
[8] A. Perelson,et al. Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection , 2009, Journal of Virology.
[9] Frank Klawonn,et al. Analysis of Practical Identifiability of a Viral Infection Model , 2016, PloS one.
[10] Alan S. Perelson,et al. Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.
[11] M. Jordana,et al. Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung , 2010, The Journal of Immunology.
[12] J. Xie,et al. Mechanisms of Severe Mortality-Associated Bacterial Co-infections Following Influenza Virus Infection , 2017, Front. Cell. Infect. Microbiol..
[13] F. Hayden,et al. Antiviral combinations for severe influenza , 2014, The Lancet Infectious Diseases.
[14] J. Rehg,et al. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. , 2002, The Journal of infectious diseases.
[15] A. Moscona. Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.
[16] R. Webster,et al. Competitive Fitness of Oseltamivir-Sensitive and -Resistant Highly Pathogenic H5N1 Influenza Viruses in a Ferret Model , 2010, Journal of Virology.
[17] A. Perelson,et al. Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae , 2013, PLoS pathogens.
[18] E. D. Kilbourne. Influenza Pandemics of the 20th Century , 2006, Emerging infectious diseases.
[19] Stephen H. D. Jackson,et al. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.
[20] Ronald Gieschke,et al. Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid , 2008, Journal of clinical pharmacology.
[21] Arjun Srinivasan,et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. , 2011, The Journal of infectious diseases.
[22] Alan S. Perelson,et al. Viral kinetic modeling: state of the art , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[23] F. Hayden,et al. Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[24] C. Beauchemin,et al. A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression , 2015, Antimicrobial Agents and Chemotherapy.
[25] J. McCullers. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. , 2004, The Journal of infectious diseases.
[26] John J. Treanor,et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .
[27] Robert Schechter,et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Laetitia Canini,et al. Population modeling of influenza A / H 1 N 1 viral kinetics and symptom dynamics , 2010 .
[29] R. Eggo,et al. Influenza Interaction with Cocirculating Pathogens, and Its Impact on Surveillance, Pathogenesis and Epidemic Profile: A Key Role for Mathematical Modeling , 2017, bioRxiv.
[30] Andreas Handel,et al. Neuraminidase Inhibitor Resistance in Influenza: Assessing the Danger of Its Generation and Spread , 2007, PLoS Comput. Biol..
[31] I. Mcnicholl,et al. Neuraminidase Inhibitors: Zanamivir and Oseltamivir , 2001, The Annals of pharmacotherapy.
[32] Andrew Hughes,et al. Model-based drug discovery: implementation and impact. , 2013, Drug discovery today.
[33] Hana M. Dobrovolny,et al. Assessing Mathematical Models of Influenza Infections Using Features of the Immune Response , 2013, PloS one.
[34] Alan S. Perelson,et al. Effects of Aging on Influenza Virus Infection Dynamics , 2014, Journal of Virology.
[35] Gilles Clermont,et al. A Dynamical Model of Human Immune Response to Influenza a Virus Infection , 2006 .
[36] A. Shahangian,et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. , 2009, The Journal of clinical investigation.
[37] M. Nowak,et al. Virus dynamics: Mathematical principles of immunology and virology , 2001 .
[38] Alan S. Perelson,et al. Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study , 2014, PLoS Comput. Biol..
[39] Laetitia Canini,et al. Population Modeling of Influenza A/H1N1 Virus Kinetics and Symptom Dynamics , 2010, Journal of Virology.
[40] J. McCullers,et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. , 2009, The Journal of infectious diseases.
[41] K. Walters,et al. Lethal Synergism of 2009 Pandemic H1N1 Influenza Virus and Streptococcus pneumoniae Coinfection Is Associated with Loss of Murine Lung Repair Responses , 2011, mBio.
[42] D. E. Rogers,et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. , 1959, The Journal of clinical investigation.
[43] J. McCullers. Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.
[44] M. Meyer-Hermann,et al. Innate Immune System Dynamics to Influenza Virus , 2012 .
[45] T. Moran,et al. Type I Interferon Induction during Influenza Virus Infection Increases Susceptibility to Secondary Streptococcus pneumoniae Infection by Negative Regulation of γδ T Cells , 2012, Journal of Virology.
[46] A. Perelson,et al. Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.
[47] M. Lipsitch,et al. Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States , 2009, PLoS currents.
[48] T. Eissing,et al. A pharma perspective on the systems medicine and pharmacology of inflammation. , 2015, Mathematical biosciences.
[49] S. Goerdt,et al. Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.
[50] Michael Meyer-Hermann,et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research , 2015, Viruses.
[51] Alan S. Perelson,et al. Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses , 2012, PLoS Comput. Biol..
[52] C. Beauchemin,et al. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. , 2011, Journal of theoretical biology.
[53] Y. Kuang,et al. Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. , 2010, Mathematical biosciences and engineering : MBE.
[54] K. Yanagihara,et al. The Effect of Intravenous Peramivir, Compared with Oral Oseltamivir, on the Outcome of Post-Influenza Pneumococcal Pneumonia in Mice , 2015, Antiviral therapy.
[55] G. Taylor,et al. Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate. , 2011, Journal of molecular biology.
[56] Niall Johnson,et al. Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.
[57] J. McCullers. The co-pathogenesis of influenza viruses with bacteria in the lung , 2014, Nature Reviews Microbiology.
[58] N. J. White,et al. Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.
[59] Anthony S Fauci,et al. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.
[60] F Y Aoki,et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. , 2003, The Journal of antimicrobial chemotherapy.